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This study identifies a developmental trajectory from human IgMhi gut homing transitional 2 
cells to marginal zone B cells, all stages of which are affected in patients with severe 





B cells emerge from the bone marrow as transitional (TS) B cells that differentiate through 
T1, T2 and T3 stages to become naïve B cells.  We have identified a bifurcation of human B 
cell maturation from the T1 stage forming IgMhi and IgMlo developmental trajectories. IgMhi 
T2 cells have higher expression of a4b7 integrin and lower expression of IL4 receptor (IL4R) 
compared to the IgMlo branch and are selectively recruited into gut-associated lymphoid 
tissue. IgMhi T2 cells also share transcriptomic features with marginal zone B cells (MZB). 
Lineage progression from T1 cells to MZB via an IgMhi trajectory is identified by pseudotime 
analysis of scRNA-sequencing data.  Reduced frequency of IgMhi gut homing T2 cells is 
observed in severe SLE and is associated with reduction of MZB and their putative IgMhi 
precursors. The collapse of the gut-associated MZB maturational axis in severe SLE affirms 











Transitional (TS) B cells are the immature B cells in human blood from which all mature B 
cells develop. Following emigration from bone marrow, TS B cells mature through T1, T2 
and T3 phases, when autoreactive cells are depleted (Palanichamy et al., 2009; Suryani et 
al., 2010; Yurasov et al., 2005).  
 
In mice, a B cell lineage split that is dependent on B cell receptor (BCR) engagement and the 
serine/threonine kinase Taok3, is initiated at the T1 phase (Hammad et al., 2017). This 
directs B cells towards marginal zone B (MZB) cell fate, requiring subsequent Notch2 
cleavage by a disintegrin and metalloproteinase-containing protein-10 (ADAM10).   
 
MZB lineage progression in humans is not clearly understood, or indeed, universally 
accepted. A MZB precursor (MZP) population has been proposed that undergoes terminal 
differentiation to MZB following NOTCH2 ligation and can be discriminated from naïve B 
cells by expression of high levels of IgM (IgMhi), CD24 and the glycosylation-dependent 
epitope CD45RBMEM55 (referred to here as CD45RB). An additional CD45RBhi IgMhi population 
that lacks the ABCB1 cotransporter has previously been referred to as T3’, although the 
relationship between this subset, MZB and MZP is unclear (Bemark et al., 2013; Descatoire 
et al., 2014; Koethe et al., 2011; Zhao et al., 2018).  
 
In humans, MZB develop over the first 2 years of life and are important for immunity against 
encapsulated bacteria (Weller et al., 2004). They undergo a phase of clonal expansion and 
receptor diversification in the germinal centres (GC) of gut-associated lymphoid tissue 
(GALT) (Zhao et al., 2018) (Weill and Reynaud, 2019). The shared expression of MAdCAM1 
between the splenic marginal zone reticular cells and GALT high endothelial venules (HEV) 
creates the potential to recruit B cells to both sites mediated by a4b7 integrin binding (Kraal 
et al., 1995; Vossenkamper et al., 2013). We have described the expression of b7 integrin 
(used here and previously as a surrogate for a4b7) by T2 B cells in humans and observed 
their selective recruitment into GALT where they become activated (Vossenkamper et al., 
2013). Therefore, exposure to the GALT microenvironment could be associated with 
multiple stages of MZB cell development from as early as the T2 stage. 
 
The systemic autoimmune disease systemic lupus erythematosus (SLE), in particular the 
severe variant lupus nephritis (LN), has markedly distorted profiles of B cell subsets in blood. 
The TS pool is expanded, as is the B cell subset lacking both CD27 and IgD (so called ‘double 
negative’ or DN B cells) (Landolt-Marticorena et al., 2011; Wei et al., 2007). 
Disproportionate expansion of a population of DN cells lacking expression of CD21 and 
CXCR5 and with upregulated CD11c (DN2 cells) is a particular feature of LN (Jenks et al., 
2018). DN2 cells may be derived from activated naïve B cells (aNAV), driven by TLR7 
engagement, resulting in the generation of self-reactive antibody producing plasma cells 
(Jenks et al., 2018; Tipton et al., 2015). Interestingly, a recent study of a cohort of newly 
diagnosed patients with SLE demonstrated that MZB may be reduced in frequency (Zhu et 
al., 2018). Since we have previously shown that TS B cells in SLE may have significantly 
reduced expression of b7 integrin, we were interested to know if this may be associated 
with defective MZB development and the increase in aNAV and DN2 cells.  
 
Here, we identify bifurcation in human B cell development from the T2 stage. Cells in one 
branch are IgMhi, express b7 integrin and are gut homing. Cells in the alternative IgMlo 
branch have high expression of IL4R, lower expression of b7 integrin and do not tend to 
enter the gut. Transcriptomically, IgMhi T2 cells share features with MZB. B cell development 
progresses from T1 to MZB via an IgMhi trajectory by pseudotime analysis.  IgMhi T2 cells are 
stably IgMhi in culture and have a greater tendency to make IL10 than IgMlo cells.   Markedly 
reduced frequency of IgMhib7hi T2 cells was seen in patients with severe SLE and this was 
associated with stark reduction in cell populations associated with MZB development. Our 
data link reduced access of IgMhi T2 cells to GALT with defects in all stages of MZB 
differentiation and enables the assimilation of these elements of human MZB differentiation 





Segregation of B cell phenotypes from T2 through naïve B cell subsets 
In mice, B cells commit to MZB differentiation soon after bone marrow emigration at the T1 
stage. To seek evidence of this in humans, a deep phenotypic analysis of peripheral blood 
mononuclear cells (PBMC) from healthy control donors (HCD) was undertaken by mass 
cytometry (Fig. S1 A, B and C). SPADE on viSNE identified B cell subsets including TS B cells 
represented by CD27-IgD+CD24+++/++CD38+++/++ nodes that included CD10+ T1 and T2 cells as 
well as CD10- T3 cells (Fig. 1 A)(Qiu et al., 2011; Zhao et al., 2018). T3 cells can only be 
definitively distinguished from naïve cells by their failure to extrude dyes such as rhodamine 
123 (R123) due to lack of the ABCB1 cotransporter (Wirths and Lanzavecchia, 2005) (Fig. S1 
D). Since mass cytometry cannot be used to detect dye extrusion, the boundary between T3 
and naïve B cells was estimated to generate the TS SPADE bubble.  
 
To perform a deep phenotypic analysis of TS B cells, events within the TS bubble identified 
in Fig. 1 A and B were exported and re-clustered by SPADE on viSNE using all expressed 
panel markers and then grouped according to gradients of loss of CD10, CD38 and CD24 and 
gain of CD21 corresponding to T1, T2 and T3 stages of differentiation (Fig. 1 B)(Bemark, 
2015). The SPADE trees branched, forming 2 chains of nodes that each extended through 
the T2 and T3 SPADE bubbles with no lateral connections between the branches. Branches 
differed most notably in their expression of IgM (Fig. 1 C). IgMhi T2 B cells also had lower 
expression of CCR7 but higher expression of b7 integrin than IgMlo T2 cells by mass 
cytometry (Fig 1. D) and qPCR (Fig. 1 E). The amount of IGHD or IGHM transcripts did not 
differ between IgMhi and IgMlo T2 cells suggesting post translational mechanisms account 
for variable surface immunoglobulin expression as previously reported (Bell and Goodnow, 
1994; Enders et al., 2014) (Fig. 1 E). Furthermore, increased IgM surface expression was not 
associated with a reduction in surface IgD expression as IgMhi T2 B cells had high expression 
of both immunoglobulin isotypes (Fig. 1 F). In addition, IgMhi T3 cells had higher median 
expression of CD24 and CD45RB than IgMlo T3 cells (Fig. 1 B and G).  
 
In the SPADE analysis of all CD19+ B cells, nodes representing IgMhi TS B cells were 
continuous with IgMhi naïve B cells and IgMlo TS B cells were continuous with IgMlo naïve 
cells (Fig. 1 A and H). Principle component analysis (PCA) using all markers expressed by cells 
in nodes identified in Fig. 1 H grouped IgMhi TS B cells closest to IgMhi naïve B cells and most 
distant to IgMlo TS B cells (Fig. 1 I). The major contributors to PCA1 and PCA2 in addition to 
IgM and IgD were mediators of cell traffic (Fig. 1 J).  
 
Human B cells therefore segregate phenotypically as T1 cells enter into the T2 stage, 
forming two branches that differ in their expression of IgM and in markers of migratory 
potential. IgMhi T2 cells resemble IgMhi naïve cells more closely than they resemble IgMlo T2 
cells with which they share markers of differentiation.  
 
Gut-associated lymphoid tissue is enriched in IgMhi T2 cells 
Human TS B cells can home to GALT where they become activated (Vossenkamper et al., 
2013). To determine whether the high expression of b7 integrin on IgMhi TS B cells is 
associated with selective recruitment into GALT, mass cytometry was used to compare B 
cells isolated from paired blood and gut biopsies from individuals undergoing surveillance 
colonoscopies (n=7) (Fig. S1 A, B and C). TS B cells are a small subset and due to low 
mononuclear cell yields from GALT biopsies, data from individual samples were 
concatenated. SPADE on viSNE was then used to identify CD10+ T1 and T2 B cells within the 
total CD19+ population (Fig. 2 A and S1 E). The undirected clustering algorithm FlowSOM 
(Van Gassen et al., 2015) was then used to group T1 and T2 B cells. This identified six 
metaclusters and the identity of each cluster was deduced from the relative expression of 
CD21, CD24, CD38 and IgM (Fig. 2 B and C). This demonstrated that IgMhi T2 cells are 
enriched in GALT, whereas both T1 and IgMlo T2 cells are depleted compared to PBMC (Fig. 
2 D and E). GALT T2 cells were predominantly represented by metacluster 4 whilst the 
majority of T2 cells in PBMC represented by metacluster 3 (Fig. 2 B and E). Metacluster 4 
had higher expression of IgM, CD5, CD24 and CD38 but lower expression of CD21, CD22, 
CD23 and CCR7 than metacluster 3 (Fig. S1 F). Within GALT IgMhi T2 cells had higher 
expression of the activation markers CD69 and CD80 than PBMC (Fig. 2 E).  
 
Having observed that IgMhi T2 cells are enriched in GALT we sought confirmation of 
selective recruitment by asking whether this population is depleted from blood that has 
passed through the gut. Blood from the gut passes to the liver via the hepatic portal vein 
that also receives a contribution from the splenic vein.  We therefore isolated lymphocytes 
from liver perfusion samples that would be depleted of cells that entered the gut. Using the 
gating strategy displayed in Fig. S 1 D, liver perfusate samples were observed to be enriched 
in T1 cells as reported previously (Vossenkamper et al., 2013)(Fig. 2 F), and that CD24hiIgMhi 
T2 and IgMhi naïve cells were depleted compared to PBMC from HCD (Fig. 2 G, H and I), 
consistent with their selective recruitment from blood into GALT.  
 
Transcriptomic analysis of IgMhi and IgMlo TS B cells demonstrates different upstream 
regulators of phenotype 
Having demonstrated contrasting surface phenotypes and migratory capacity of IgMhi and 
IgMlo TS B cells, we next sought to identify transcriptomic features differing between them 
and to gain insight into inducers and regulators of these subsets by single cell RNA 
sequencing. IgMhi and IgMlo TS B cells from 5 HCD were sorted by FACS, pooled and gene 
expression libraries were prepared using a 10x Genomics single cell 5’ gene expression 
workflow (Fig. S2 A, B, C and D). In total, 14499 genes were identified in 4268 cells after 
quality filtering. The non-linear dimension reduction algorithm UMAP (Becht et al., 2018) 
was run on differentially expressed genes and demonstrated discreet clustering of IgMhi and 
IgMlo TS B cells (Fig. 3 A).  Selected genes from the top 60 differentially expressed genes are 
illustrated in Fig. 3 B and C. Transcripts encoding CD1C and MZB1 that are expressed by MZB 
cells, were amongst the most abundantly expressed genes in IgMhi TS B cells. The lupus risk 
allele and regulator of toll like receptor 9 (TLR9) responses PLD4 was the most highly 
differentially expressed gene in IgMhi TS B cells (Gavin et al., 2018). Undirected clustering of 
pooled IgMhi or IgMlo TS B cells generated clusters that contained predominantly IgMhi or 
IgMlo TS B cells (Fig. 3 D and E) that shared enrichment of the genes expressed by these cell 
subsets (Fig. 3 B and F). High expression of IL4R by IgMlo TS and IgMlo naïve B cells was 
confirmed by flow cytometry (Fig. S2 E and F). Importantly, KLF2, which drives murine 
follicular B cell development, was upregulated in IgMlo TS B cells (Hart et al., 2011). CCR7 
was upregulated in IgMlo TS B cells supporting the higher surface expression that was 
evident in the mass cytometry analysis. Higher abundance of transcripts encoding L-selectin 
by IgMlo TS B cells was also confirmed by qPCR using sorted populations (Fig. S2 G and H).  
 
Ingenuity pathway analysis demonstrated enrichment of retinoic acid receptor and 
lipopolysaccharide induced genes in IgMhi TS B cells (Fig. S2 I and J). IgMlo TS B cells were 
enriched in genes induced by interferon-g (IFN-g), interleukin-1 and interleukin-2 (Fig. S2 K). 
IgMhi TS B cells used less VH1 and more VH3 than IgMlo TS B cells consistent with published 
profiles of MZB repertoire (Bagnara et al., 2015)(Fig. S2 L).   
 
IgMhi and IgMlo TS B cells therefore have distinct transcriptomes. IgMlo cells are selectively 
enriched in genes encoding peripheral circulation and inhibition of marginal zone B cell fate 
whereas IgMhi cells have gene expression signatures and IGHV gene family usage linking 
them to MZB cells. 
 
The abundance of CD1C transcripts in IgMhi TS B cells was of particular interest because 
CD1c is characteristically highly expressed by human MZB (Weller et al., 2004). Consistent 
with the transcriptomic profile, CD1c surface expression was higher on IgMhi than IgMlo TS B 
cells (Fig. 3 G and H). As previously reported CD1c expression was high on MZB (Fig. 3 I) as 
well as on MZP and CD45RBhi T3 cells (previously referred to as T3’) that have been linked to 
MZB development (Bemark et al., 2013; Descatoire et al., 2014; Koethe et al., 2011; Zhao et 
al., 2018). MZP and CD45RBhi T3 cells were defined by the phenotype CD27-IgD-CD10-
CD45RBhi with expression of the ABCB1 cotransporter or not, respectively (Fig. S1 D, Fig. 3 J, 
K and L). Cells that express the ABCB1 cotransporter extrude rhodamine 123 (R123) and are 
therefore identified as R123lo cells in this analysis. Both subsets share high expression of IgM 
and CD24 (Fig. S2 M and N). 
 
Lineage progression from IgMhi TS B cells through to MZB 
The shared surface properties of IgMhi TS with IgMhi naïve B cells (Fig. 1 I), the enrichment of 
transcripts considered characteristic of MZB in IgMhi TS (Fig. 3 B and F), and shared high 
expression of CD1c by IgMhi TS with MZB and other B cell subsets associated with MZB 
development (Fig. 3 H and L) all support the existence of an IgMhi MZB differentiation 
pathway that begins during TS B cell development. We investigated this further by 
performing pseudotime trajectory analysis of single cell RNA sequencing data from HCD B 
cells from blood.  
 
CD19+ B cells were sorted from PBMC of 3 HCD (Fig. S3 A) and surface labelled with Total-
Seq-C antibodies prior to capture on the 10x chromium controller (Fig. S3 B). Gene 
expression, and antibody detection tag (ADT) libraries were then prepared according to the 
manufacturer’s instructions and sequenced on an Illumina HiSeq High Output platform (Fig. 
S3 C).  
 
Data from single HCD were initially analysed individually. UMAP plots were used to visualize 
clusters and identify the B cell subsets they corresponded to by overlaying signal from 
lineage defining transcripts and CITE-Seq antibodies (Fig. S3 D, E).  TS B cells were identified 
as CD27-IgD+ clusters with high surface expression of CD38.  Of the remaining CD27-IgD+ 
clusters that represented naïve cells, those with the top 30% of median IgM-ADT signal were 
designated IgMhi (Fig. S3 D, E, F and G).  Note that because identification of MZP and 
CD45RBhi T3 would require reagents that are incompatible with this method (Fig. 3 J), they 
will be included in the IgMhi naïve cell groups in this analysis. CD27+IgD+ clusters that were 
enriched in CD1C transcripts were designated as MZB. CD27+IgD-IgM+ clusters were 
designated ‘IgM-only’ cells and CD27+IgD-IgM- clusters enriched in HOPX and COCH 
transcripts were designated as class switched memory B cells (CSM) (Descatoire et al., 
2014)(Fig. S3 D, E, F and G).  
 
Three dimensional UMAP plots were then used to better visualise the spatial relationship 
between these B cell subsets (Fig. 4 A, B, C and D and S3 H and I). This demonstrated clear 
separation of CD27+ and CD27- ‘islands’ of cells (Fig. 4 A, B, C and D, Fig. S3 H and I and 
Supplemental videos 1, 2 and 3).  In all three HCD two distinct cellular ‘bridges’ linked the 
CD27- and CD27+ islands in the plot (Fig. 4 A, B and S3 H and I and Supplemental videos 1, 2 
and 3).  In each HCD, an IgMhi bridge that was enriched in cells with CD1C transcripts linked 
the CD27- island to MZB. (Fig. 4 A, B, C and D and S3 H and I). In contrast, IgM-only cells 
were connected to the CD27- island by naïve cells with lower expression of IgM.  
 
Having visualized the juxtaposition of IgMhi naïve cells with MZB in UMAP clusters we next 
used the Slingshot tool for pseudotime trajectory analysis. Data from the three HCD were 
normalized and integrated. UMAP plots were used to identify clusters representing 27-
CD38hiCD24hi TS cell and CD27+IgD+IgM+ MZB subsets by overlay of CD27, IgM, IgD and CD38 
ADT signal (Fig. 4E and F). The TS B cell cluster was selected as the starting point for analysis 
of pseudotime transitions in Slingshot. Importantly, end points were not specified. 
 
Slingshot identified an IgMhi pseudotime trajectory from TS that passed through the MZB 
cluster via IgMhi naïve B cells (Street et al., 2018) (Fig. 4 G and Supplemental video 4). 
Amongst the 100 most differentially expressed genes along this trajectory were PLD4, CD1C, 
SOX4 and MZB1, that were previously identified as differentially expressed between IgMhi 
and IgMlo TS B cells (Fig. 3B and F and Fig. 4 H and I). Analysis of gene expression by cells 
along the trajectory demonstrated progressive downregulation of IGLL5 and VPREB1 
markers of B cell immaturity (Fig. 4 H). Upregulated in the terminal stages of the trajectory 
were genes encoding proteins implicated in cell adhesion, including ITGB2, PCDH9 and 
activation including DAPP1 (Fig. 4 H and I). The final cluster in the pseudotime trajectory was 
enriched in interferon regulated genes MX1 and transcription factor ZEB2 (Fig. 4 H and I). 
IFN induced genes as well as DAPP1 and FCRL5 are highly expressed by DN2 cells, although 
the relationship of this subset with MZB is not known (Jenks et al., 2018). Pseudotime 
analysis of HCD PBMC therefore identified an IgMhi developmental trajectory from TS B cells 
to MZB.  
 
IgMhi and IgMlo TS B cells differ functionally, and in their potential to differentiate  
We next determined if IgMhi and IgMlo TS B cells that have different cell surface and 
transcriptomic characteristics maintain their relative levels of IgM expression in vitro 
following stimulation and if they differ functionally. Initially, proliferation in response to 
anti-IgM in the presence of CD40L was measured. IgMhi TS B cells proliferated more than 
IgMlo cells in response to anti-IgM (Fig. 5 A and B). Next we investigated the response of 
IgMhi and IgMlo TS B cells to the TLR9 agonist CpG, that has been proposed to drive MZB 
differentiation (Guerrier et al., 2012). In culture, CpG increased surface expression of IgM on 
both IgMhi and IgMlo B cells. However, IgMhi cells remained IgMhi compared to the IgMlo cells 
(Fig. 5 C and D). Furthermore, culture with CpG resulted in greater upregulation of CD45RB 
on IgMhi TS and IgMhi naïve cells than IgMlo TS and IgMlo naïve cells, consistent with 
adoption of an MZP like phenotype (Fig. 5 E).  
 
A subpopulation of human cells with a TS phenotype are regulatory, and murine IL10 
producing B regulatory (Breg) cells are T2 marginal zone progenitor cells and the gut is 
important for their induction (Blair et al., 2010; Pillai et al., 2005; Rosser et al., 2014). We 
therefore investigated the capacity of IgMhi TS B cells to produce IL10. Following 6 hours 
stimulation with PMA and ionomycin, IgMhi TS B cells produced significantly more IL10 than 
IgMlo cells (Fig. 5 F), inferring greater regulatory capacity of this subset.  
 
Marginal zone B cell differentiation is defective in patients with severe SLE 
We have previously observed reduced frequencies of circulating TS B cells expressing b7 
integrin in a subset of SLE patients, implying reduced potential for TS B cells to access GALT 
in these cases. Data presented here implicates GALT as an important site for MZB 
differentiation and MZB depletion has been reported in SLE (Rodriguez-Bayona et al., 2010; 
Zhu et al., 2018). Hence, we sought to determine whether the stages of our proposed MZB 
differentiation pathway were affected in SLE.   
 
Flow cytometry was used to quantify B cell subsets in a cohort of 41 SLE patients and 
matched HCD (Fig. S4 A and B). Reduced MZB frequency was seen in patients with SLE 
compared to HCD (Fig. 6 A and B) and this was most marked in patients with lupus nephritis 
(LN) compared to patients with other manifestations of SLE (OL) (Fig. 6 C). Reduced MZB 
frequency was not a feature of other autoimmune diseases studied (Fig. 6 C, Fig. S4 C),  
although it has been identified in patients with Sjögren’s disease (Roberts et al., 2014). We 
found that a relative reduction of MZB in patients with SLE was associated with a reduction 
of MZP (CD27-IgD+CD10-CD45RBhi R123-) (Fig. 6 D and E) and T3 CD45RBhi cells (CD27-
IgD+CD10-CD45RBhiR123+)(Fig. 6 D and F). This was again most consistently observed in the 
LN patient cohort. The proportion of naïve B cells (CD27-IgD+CD10-R123lo) was also 
diminished in SLE (Fig. 6 G) but CD45RBloR123hi cells were more frequent (Fig. 6 H). This 
population was further divided into T3 and aNAV by their expression of CD24 and CD38 (Fig. 
6 I). CD45RBloR123hi cells were predominantly T3 cells (Fig. 6 J), although both subsets were 
increased in patients with LN (Fig. 6K and L). Reduced frequency of MZB and precursor 
populations was not secondary to demographics or immunosuppressants but was more 
marked in more severe disease (Fig. S5 A, B, C ,D and E).  As previously reported, CD27-IgD- 
DN cells were more abundant in LN (Fig. 6 M). These were predominantly CD24loCD21lo and 
therefore DN2 consistent with other studies (Fig. 6 N and O) (Jenks et al., 2018). 
 
MZB depletion in SLE is therefore associated with reduced frequency of MZP and T3 
CD45RBhi cells. This consolidates the concept of these cells as being in a developmental 
continuum in health and suggests that altered transitional B cell maturation or migration 
may result their depletion from the blood in SLE. 
 
IgMhi b7 integrinhi T2 cells are reduced in frequency in lupus nephritis 
To identify early stages of aberrant marginal zone lineage development in LN we used mass 
cytometry to compare blood B cell subsets from LN patients and HCD in an undirected way 
(Fig. S1 A, B and C). The automated clustering algorithm CITRUS identified populations that 
differed significantly in abundance between LN and HCD. The three main clusters of nodes 
(Fig. 7 A) can be identified by their relative expression of B cell lineage markers (Fig. 7 B and 
C). CD27-IgD+CD10- CD45RBhi (MZP) and CD27+IgD+CD10- CD45RBhi (MZB) cells were 
significantly reduced in LN patients (Fig. 7 Ci and Cii). TS B cells were more abundant (Fig. 7 
Ciii) whilst IgA class switched cells were reduced in patients with LN (Fig. 7 Civ).  
 
TS B cell subpopulations in HCD and LN were quantified by FlowSOM (Fig. 7 D and E). 5 
metaclusters were identified representing subdivisions of T1 and T2 populations (Fig. 7 D). 
Inspection of minimal spanning trees demonstrated stark reduction of certain TS 
subpopulations in LN (Fig. 7 E). Quantification of events within metaclusters from all donors 
revealed that T1 cells represented by metaclusters 1,2 and 3 were more abundant in LN 
whilst IgMhi T2 cells with high expression of b7 integrin represented by metacluster 4 were 
markedly less abundant in LN patients (Fig. 7 F).  
 
Reduced frequency of IgMhi T2 cells with high expression of b7 integrin is therefore 
associated with MZB depletion in LN patients. This supports the association between MZB 
and IgMhi T2 cells in health and implicates reduced access of these cells to GALT in the 




We have identified branches of human B cell lineage maturation that are evident from the 
T2 stage.  An IgMhi branch, that expresses higher levels of b7 integrin and lower levels of 
IL4R compared to the IgMlo branch, is gut homing. Confirmation of differentiation through 
IgMhi stages of differentiation from IgMhi T2, including IgMhiCD45RBhi T3 and naïve B cell 
variants to MZB is gained from pseudotime analysis coupled with the observed concerted 
reduction of the stages in this sequence in patients with severe SLE (Fig. S5 F).  
 
The reduced frequencies of gut homing IgMhi T2 cells in severe SLE further consolidates the 
role of GALT in early B cell fate decisions and supporting MZB development. Although It is 
not clear if reduced frequency of cells in this pathway in blood reflects defects in 
differentiation, alternative homing patterns or cell death, the absence of the gut homing 
MZB maturational axis in blood in severe SLE affirms its existence in health. It is also not 
clear whether alteration of our proposed MZB differentiation pathway is a causative factor 
or a consequence of inflammation. The inverse correlation of MZB counts and disease 
activity may support the latter. 
 
We have previously observed that human T2 cells are recruited into GALT where they are 
activated by intestinal microbes (Vossenkamper et al., 2013). Here we demonstrate that 
specifically the IgMhi T2 subset of TS B cells is recruited into GALT, where they have a 
phenotype of activated cells including expression of CD69 and CD80. The IgMhi T2 subset is 
also enriched in ROR and LPS inducible genes, consistent with exposure to the microbiota. 
We show that the TLR9 agonist CpG that upregulates IgM and NOTCH2 in human TS B cells 
(Capolunghi et al., 2008; Guerrier et al., 2012) also upregulates CD45RB on IgMhi TS and 
IgMhi naïve cells. PLD4, that is a lupus risk allele and the most highly upregulated gene in 
IgMhi compared to IgMlo TS B cells, is upregulated along the developmental pathway to MZB 
and limits responses to CpG (Gavin et al., 2018). This suggests that PLD4 defects could 
contribute to SLE pathogenesis by impacting an aspect of the development or function of 
IgMhi TS B cells involving TLR9. Interestingly, PLD4 is also expressed in the splenic marginal 
zone in mice (Yoshikawa et al., 2010) and PLD4 knockout mice develop autoantibodies and 
immune complex mediated renal damage similar to SLE with LN (Gavin et al., 2018).  IgMhi 
TS B cells also show a transcriptomic signature indicative of retinoic acid regulation that is a 
feature of GALT microenvironment. Together, these data suggest that innate signals and the 
gut environment impact the origin, fate and function of IgMhi TS B cells.  
 
Consistent with proposed developmental continuum from the IgMhi T2 stage through to 
MZB, GALT is involved in MZB development, including a stage of receptor diversification in 
GALT GC. However, supporting a relatively short-term transit coupled to differentiation, the 
frequencies of somatic mutations in MZB are lower than those of memory B cells or plasma 
cells in the gut (Zhao et al., 2018). Together these data suggest that GALT transit and GC 
occupancy are important but transient phases in IgMhi T2 to MZB lineage progression. 
Pseudotime analysis also identified a population of B cells that appear to develop from MZB 
and that are activated and more mature. It is possible that activation of MZB might generate 
a novel population of effector or memory cells. 
 
MZB differentiation is associated with distinctive gene expression changes and acquisition of 
the transcription factor ZEB2 (SIP1). ZEB2 has previously been identified as a component of 
a network including miR200 and TGF-b1 that can regulate cell fate decisions (Gregory et al., 
2008; Guan et al., 2018). Activated TGFb-1 is produced abundantly in the gut. It is possible 
that in addition to playing important roles in regulation of intestinal immunity as a switch 
factor for IgA and induction of regulatory T cells, it could also be involved in gut-associated 
MZB development by interactions with ZEB2 (Borsutzky et al., 2004; Chen et al., 2003).  
 
Alteration of the MZB developmental pathway in the blood of severe SLE patients was 
accompanied by expanded T3, aNAV and DN2 cell populations. Expansion of aNAV and DN2 
populations is a product of excessive TLR7 and IFN-g signalling. We were therefore 
interested in enrichment of IFN-g induced genes in IgMlo TS B cells. Interestingly, the IFN-g 
regulated transcription factor KLF2 was transcriptionally upregulated in IgMlo TS B cells. KLF2 
drives follicular B cell maturation in mice and its deletion results in an expansion of MZB 
cells. The role of KLF2 in human B cell development is not known, however loss-of-function 
KLF2 mutations along with NOTCH2 mutations that increase the stability of the notch 
intracellular domain are the most commonly encountered mutations in human MZB cell 
lymphoma (Campos-Martin et al., 2017). This implicates KLF2 in human B cell fate decisions 
and eludes to a role for IFN-g in B cell development and supports its proposed involvement 
of the imbalance of B cell subsets in LN. The role of IFN-g in defective MZB maturation is also 
supported by reduction of this subset in patients with severe COVID-19, which is associated 
with elevated serum IFN-g levels and extrafollicular B cell responses (Laing et al., 2020; 
Woodruff et al., 2020).  
 
LN represents a severe lupus subtype associated with the worst clinical outcomes (Yap et 
al., 2012). B regulatory (Breg) IL10 responses associated with expression of CD80 and CD86 
are defective in SLE (Blair et al., 2010), permitting aberrant T effector functions (Oleinika et 
al., 2019). In mice Breg cells are IgMhiCD21hiCD23hi T2 MZP cells and interaction with the gut 
microbiome is essential for their induction (Evans et al., 2007; Rosser et al., 2014). We have 
identified that IgMhi TS B cells express CD80 in GALT and represent the predominant IL10 
producing TS B cell subset. Their reduction in LN may be synonymous with the loss of Breg 
IL10 responses and associated with the lack of T cell regulation in SLE. MZB confer immunity 
to encapsulated bacteria such as pneumococcus, thus their reduction in LN may confer 
increased risk of such infections SLE (Danza and Ruiz-Irastorza, 2013). This also reinforces 
the importance of pneumococcal vaccination in this patient cohort. 
 
Undirected analysis of B cells in blood in LN compared to HCD identified reduction in IgA 
memory B cells in LN. IgA deficiency can be observed in SLE, though the mechanism driving 
this is not known (Cassidy et al., 2007; Odineal and Gershwin, 2020).  It’s possible that lower 
expression of b7 integrin by B cells could contribute to IgA deficiency in SLE.  
 
In summary, we identify an MZB maturation pathway that becomes evident at the T2 stage 
of B cell development and that is depleted in severe SLE. Traffic through GALT is a 
component of this pathway that is potentially linked to the induction of human IL10 
producing Breg cells (Rosser et al., 2014). Together, this affirms the importance of tissue 
microenvironments in shaping the B cell functional repertoire and maintaining health.  
Understanding the regulators of early B cell fate will be a key to resolving the disturbances 
in B cell function in severe SLE. 
Figure legends 
 
Figure 1. Segregation of B cell phenotypes from T2 through naïve B cell subsets. 
A) SPADE on viSNE plots generated using the following markers that were used to identify 
B cell subsets; CD10, CD24, CD27, CD38, CD45RB, IgD, IgM, IgA and IgG. The plots are 
from a female HCD and are representative of 10 HCD. Nodes represent a cluster of 
phenotypically similar cells, the size of a node is proportional to the number of cells 
represented by it and the colour indicates the median expression of a given marker. 
Nodes representing B cell subsets were grouped into bubbles as indicated by the 
schema to the left of the Figure panel.  
B) SPADE on viSNE plots of TS B cells exported from the TS SPADE bubble in Figure part A 
and generated by re-running viSNE using all expressed B cell markers. The SPADE plots 
depicted are from a female HCD and are representative of 10 HCD. TS B cell populations 
were defined as T1 (CD10+CD24+++CD38+++CD21lo), T2 (CD10+CD24++CD38++CD21hi) and 
T3 (CD10-CD24+CD38+CD21hi).  
C) SPADE trees demonstrating that T2 and T3 TS B cells have prominent IgMhi and IgMlo 
subpopulations.  
D) SPADE trees demonstrating that IgMhi T2 B cells have higher expression of β7 integrin 
and lower expression of CCR7 than IgMlo T2 B cells.  
E) qPCR quantification of CCR7, ITGB7 (β7 integrin), IGHM and IGHD transcripts from 
sorted subsets expressed as 2-𝚫CT values relative to 18S endogenous control (paired t 
test). *, P<0.05; **, P<0.01. 
F) SPADE demonstrating that IgMhi T2 B cells also have high surface IgD expression.  
G) SPADE aligns IgMhi T2 cells with IgMhi T3 cells with relatively high expression of CD45RB.  
H) A SPADE on viSNE plot from Figure part A demonstrating the identification of IgMhi TS 
and naïve B cell populations.  
I) A principle component analysis plot generated using all expressed markers on IgMhi and 
IgMlo subsets identified in Figure part H. Data points represent individual HCD (n=10) 
and are surrounded by 95% confidence ellipses with a larger central mean data marker.  
J) Variable contribution bar graphs demonstrate that homing receptors are major 
contributors to PCA1 and PCA2 in Figure part I.  The dashed red reference line 
represents the value were the contribution uniform.  
  
Figure 2. Gut-associated lymphoid tissue is enriched in IgMhi T2 cells. 
A) SPADE on viSNE plots depicting the expression of B cell lineage markers used to identify 
T1 and T2 cells as CD27-IgD+CD10+ in a concatenated (n=7) GALT sample, M only = IgM 
only memory (CD27+IgD-IgM+), GC = germinal centre (IgD-CD10+), PB = plasmablast (IgD-
CD38hi) (see also Fig. S1 E).  
B) A minimal spanning tree generated by FlowSOM run on exported events (n= 4520 from 
each tissue) from the TS bubble in Figure part A using CD10, CD24, CD38 and IgM as 
clustering parameters. The tree displayed shows aggregated events from both 
concatenated GALT and PBMC samples. Automatic metaclustering of the flowSOM 
nodes identified 6 metaclusters, the identity of each can be inferred by the relative 
expression of CD21, CD24, CD38 and IgM (see also Figure part C).  
C) Minimal spanning trees showing expression of CD21, CD24, CD38 and IgM on a 
concatenated (n=7) PBMC sample. Clusters represent phenotypically similar cells, their 
size is proportional to the number of cells contained within them and their colour 
indicates the median expression of a given marker.  
D) Pie charts demonstrating the proportion of TS B cell subsets inferred from metaclusters 
in Figure part B confirm that GALT is enriched in IgMhi T2 cells.  
E) Minimal spanning trees demonstrating higher expression of CD69 and CD80 on GALT TS 
B cells.  
F) Flow cytometry contour plots of concatenated (n=3) liver perfusate samples and 
concatenated HCD PBMC (n=3). TS B cells were gated as CD27-IgD+CD10+ as illustrated in 
Fig. S1 D. A reduced proportion of CD24++CD38++ T2 cells was observed in liver 
perfusates.  
G) Flow cytometry plots of concatenated liver perfusate and PBMC samples demonstrating 
T2 cells as gated in Figure part F and naïve (CD27-IgD+CD10-) B cells as gated in Fig. S1 D.  
A reduced frequency of IgMhiCD24hi T2 and naïve cells was observed in liver perfusate 
samples compared to HCD PBMC.  
H) Flow cytometry dot plots with IgM MFI overlay of concatenated PBMC (n=3) and liver 
perfusate (n=3) samples demonstrating reduced frequency of IgMhiCD24hi TS and naïve B 
cells in liver perfusate samples.   
I) Scatter plots of flow cytometry data from individual samples gated as in Figure part G 
demonstrating reduced frequency of IgMhiCD24hi TS and naïve B cells (CD27-IgD+CD10-) 
in liver perfusate samples compared to PBMC (median values). 
 
Figure 3. Transcriptomic analysis of IgMhi and IgMlo TS B cells demonstrates different 
upstream regulators of phenotype. 
A) UMAP plot of IgMhi and IgMlo TS B cells from 5 HCD (see Fig.  S2 A, B, C and D) clustered 
according to differentially expressed genes identified using the Seurat SCTransform 
workflow (Hafmeister, 2020). 
B) Heatmap of selected genes from the top 60 differentially expressed genes in IgMhi and 
IgMlo TS B cells. 
C) Scatter plot demonstrating genes differentially expressed in IgMhi and IgMlo TS B cells.  
D) A PCA based approach based on differentially expressed genes identified 6 clusters 
among the IgMhi and IgMlo TS B cells that were demonstrated by UMAP. 
E) Quantification of the frequency of IgMhi or IgMlo TS B cells within the clusters 
demonstrated by UMAP in Figure part D reveals that IgMhi TS B cells dominate in clusters 
0 and 2 and IgMlo TS B cells in clusters 1 and 3.  
F) Dot plot demonstrating expression of selected genes within clusters 0-3. 
G) Flow cytometry dot plots demonstrating CD27-IgD+CD10+ cells as gated in Fig. S1 D. T2 
cells were gated as CD24++CD38++ and IgMhi and IgMlo subsets as 30% of cells with the 
highest and lowest expression of IgM respectively.  
H) Scatter plots demonstrating CD1c MFI in T1, IgMhi and IgMlo T2 B cells gated in Figure 
part G (mean +/- SD, paired t test). *, P<0.05; ***; P<0.001; ****, P<0.0001. 
I) Histograms demonstrating CD1c MFI in B cell subsets as gated in Fig. S1 D.  
J) Dot plot of flow cytometry data demonstrating CD27-IgD+CD10- cells as gated in Fig. S1 
D. Differential expression of CD45RB and R123 allowed the identification of CD45RBhi T3 
(R123+) and MZP (R123-) cells.   
K) A histogram showing CD1c MFI on subsets as gated in Figure part J.  
L) Dot plots demonstrating CD1c MFI on subsets gated in Figure part J (mean +/- SD, paired 
t test). ***, P<0.001; ****, P<0.0001. 
 
 
Figure 4. Lineage progression from IgMhi TS B cells through to MZB. 
A) A 3D UMAP plot of CD19+ cells from a HCD (10x HCD1, see Fig. S3 C) generated from a 
PCA run on 2000 differentially expressed genes. Clusters were merged and 
pseudocoloured according to the B cell subsets they represent as described in Fig. S3 D, 
E, F and G.  
B) CD27 and IgM ADT and CD1C gene signal overlay on the 3D UMAP plot displayed in 
Figure part A.  
C) The 3D UMAP plot displayed in Figure part A viewed using different UMAP axis 
coordinates.    
D) CD27 and IgM ADT and CD1C gene signal overlay on the 3D UMAP projection in Figure 
part C.  
E) A UMAP plot generated by integrating 3 HCD 10x datasets (see Fig. S3 C) and generated 
from a PCA run on 2000 variably expressed genes.  
F) Feature plots demonstrating overlay of ADT signal on the UMAP plot from Figure part E 
enables identification of clusters representing TS and MZB cells.  
G) A Slingshot developmental trajectory overlaid onto the UMAP plot from Figure part E 
demonstrating developmental progression from clusters representing TS B cells to MZB 
via IgMhi naïve B cells.  
H) A heatmap of selected genes from the top 100 most differentially expressed genes along 
the Slingshot trajectory demonstrated in Figure part G. 
I) Feature plots demonstrating overlay of gene signal from the differentially expressed 
genes along the Slingshot trajectory identified in Figure part G.  
 
Figure 5. IgMhi and IgMlo TS B cells differ functionally and in their potential to 
differentiate. 
A) Histograms of flow cytometry data demonstrating cell trace violet (CTV) dilution following 
5 days of culture with CD40L+anti-IgM in IgMhi and IgMlo TS B cells from a HCD.  
B) Scatter plots demonstrating increased proliferation of IgMhi TS compared to IgMlo TS B 
cells when stimulated with CD40L+anti-IgM for 5 days (medians, Wilcoxon test). *, 
P<0.05. 
C) Flow cytometry contour plots demonstrating that an IgMhi phenotype is maintained on 
IgMhi TS B cells after CpG stimulation for 5 days. 
D) Scatter plots demonstrating that an IgMhi phenotype is maintained on IgMhi TS B cells 
after CpG stimulation for 5 days (mean +/- SD, paired t test). **, P<0.01. 
E) Flow cytometry contour plots and scatter plots demonstrating greater upregulation of 
CD45RB by IgMhi than IgMlo TS and naïve (CD27-IgD+CD10-) B cell subsets at day 5 culture 
with CpG (mean +/- SD, paired t test). *, P<0.05; **, P<0.01. 
F) Flow cytometry contour plots and scatter plots demonstrating higher frequency of IL10 
expressing cells among IgMhi TS B cells following 6 hour stimulation with 
PMA/ionomycin (median, Wilcoxon test). *, P<0.05. 
 
Figure 6. Marginal zone B cell differentiation is defective in patients with severe SLE. 
A) Flow cytometry dot plots and scatter plots demonstrating reduced frequency of 
CD27+IgD+ (MZB) cells in a patient with SLE compared to a HCD. 
B) Scatter plots of flow cytometry data demonstrating reduced frequency of MZB in 
patients with SLE compared to HCD (medians, Mann-Whitney test). ****, P<0.0001. 
C) Scatter plots of flow cytometry data demonstrating reduced MZB frequency in lupus 
nephritis (LN), other lupus subtypes (OL) but not in ulcerative colitis (UC), 
granulomatosis with polyangiitis (GPA) and pemphigus vulgaris (PV) (medians, Mann-
Whitney test). ***, P<0.001; ****, P<0.0001. 
D) Flow cytometry dot plots of a HCD and an SLE patient demonstrating identification of T3 
(R123hi) and naïve (R123lo) subsets with high and low expression of CD45RB. Stark 
reduced frequency of CD45RBhi T3 and naïve (MZP) populations is evident in SLE.  
E) Scatter plot of flow cytometry data demonstrating reduced frequency of MZP 
(CD45RBhiR123lo) cells in LN patients (medians, Mann-Whitney test). *, P<0.05; **, 
P<0.01; ****, P<0.0001. 
F) Scatter plot of flow cytometry data demonstrating reduced frequency of CD45RBhi T3 
(R123hi) cells in LN patients (medians, Mann-Whitney test). ***, P<0.001. 
G) Scatter plot of flow cytometry data demonstrating reduced frequency of naïve 
(CD45RBloR123lo) cells in LN patients (mean +/- SD, unpaired t test). *, P<0.05; **, 
P<0.01.  
H) Scatter plot of flow cytometry data demonstrating enrichment of CD45RBloR123hi cells in 
LN patients (mean +/- SD, unpaired t test). *, P<0.05; ***, P<0.001; ****, P<0.0001. 
I) Gating strategy to distinguish T3 (TS3) and aNAV subsets amongst R123hiCD45RBlo cells 
on the basis of CD24 and CD38 expression.  
J) Scatter plot demonstrating that R123hiCD45RBlo cells were mostly T3 cells as gated in 
Figure part I (mean +/- SD).  
K)  Scatter plot demonstrating increased frequency of T3 cells in OL and LN patients (mean 
+/- SD, unpaired t test). *, P<0.05; ****, P<0.0001. 
L) Scatter plot demonstrating increased frequency of aNAV cells in OL and LN patients 
(mean +/- SD, unpaired t test). **, P<0.01.  
M) Scatter plots showing the proportion of CD27-IgD- B cells as gated in Figure part A 
demonstrate increased frequency of this population in LN (medians, Mann-Whitney 
test). *, P<0.05.  
N) Flow cytometry dot plot demonstrating the identification of DN1 and DN2 cells based on 
expression of CD21 and CD24. 
O) Scatter plot showing that DN2 cells as gated in Figure part N were more abundant in LN 
and OL patients than in HCD (medians, Mann-Whitney test). ****, P<0.0001. 
 
Figure 7. IgMhi b7 integrinhi T2 cells are reduced in frequency in lupus nephritis. 
A) CITRUS trees generated from CD19+ cells from HCD (n=8) and LN patients (n=8) and 
clustered according to the expression of CD5, CD9, CD10, CD24, CD27, CD38, CD45RB, 
IgD, IgM and IgA (see also Fig. S1 A, B and C, Fig. S4 A). CITRUS trees represent nodes 
redundantly so that the most peripheral nodes contain cell populations that are 
progressively shared by more central nodes with the central node containing all events. 
Red nodes indicate significantly different population abundances between HCD and LN 
patients. A grey background is automatically assigned to aggregates of significant nodes. 
Arrows and roman numerals indicate nodes further analysed in Figure part C.  
B) CITRUS trees demonstrating the median expression of the clustering panel markers in 
the nodes. 
C) Histograms demonstrating the abundance and expression of panel markers in selected 
nodes, the identify of these nodes can be inferred as (i) MZP, (ii) MZB, (iii) TS B cells and 
(iv) class switched IgA memory.   
D) Minimal spanning tree generated by FlowSOM from events exported from CITRUS node 
(iii) representing TS B cells identified in Figure parts A and C. This generated 5 
metaclusters, the identification of each could be inferred by median expression of panel 
markers in each metacluster. 
E) Minimal spanning trees generated by FlowSOM plots demonstrating CD38 expression in 
a representative HCD and LN patient. Prominent skewing of TS B cell subpopulations is 
evident in LN.  
F) Relative abundances of metaclusters as a percentage of TS B cells indicate reduced 
frequency of events within metacluster 4 corresponding to IgMhi β7hi TS B cells in LN, 
and increased frequency of events in metaclusters 1,2 and 3 corresponding to T1 cells 
(medians, Mann-Whitney test). **, P<0.01; ***, P<0.001. 
 
  
Legends to Supplementary Figures 
 
Figure S1. Mass cytometry antibody panels, normalization and gating strategy. 
A) Mass cytometry panel used for analysis in Fig. 1 (panel A), Fig. 2 (panel B) and Fig. 7 
(panel C).  
B) Pre- and post- normalization plots of mass cytometry data used for Fig. 1 which is 
representative for the mass cytometry data used in Fig. 2 and 7.  
C) Gating strategy of mass cytometry data to identify live CD19+ B cells. Cleanup Residual, 
Centre, Offset and Length gates were not used for the data displayed in Fig. 2.  
D) Flow cytometry plots demonstrating identification of T1 and T2 cells as CD27-IgD+CD10+ 
cells that are CD24+++/CD38+++ and CD24++/CD38++ respectively, T3 as CD27-IgD+CD10-R123hi 
and naïve (N) B cells as CD27-IgD+CD10-R123lo. CSM = class switched memory, DN = double 
negative B cells.  
E) Spade trees demonstrating expression of IgM and CD45RB in the concatenated GALT 
sample (see also Fig. 2 A).  
F) Heatmap demonstrating the median expression of panel markers from metaclusters 3 
and 4 displayed in Fig. 2 B. 
 
Figure S2. Sort strategy, 10x genomics workflow and validation.  
A) FACS sort strategy to identify IgMhi and IgMlo TS B cell subsets.  
B) Purity plots of sorted IgMhi and IgMlo TS B cell subsets.  
C) 10x genomics experimental workflow detailing pooling of HCD samples.  
D) Summary table of cell numbers captured by the 10X controller and sequencing depth of 
IgMhi and IgMlo TS B cell subsets.  
E) Violin plot demonstrating expression of the IL4R gene in IgMlo TS B cells.  
F) Scatter plots of flow cytometry data demonstrating higher frequency of IL4R on IgMlo 
compared to IgMhi TS (CD27-IgD+CD10+) and naïve (CD27-IgD+CD10-) cells (mean +/- SD, 
paired t test). *, P<0.05.  
G) Violin plot demonstrating expression of the SELL (CD62L) gene in IgMlo TS B cells.  
H) qPCR confirms higher levels of the SELL gene transcript in IgMhi TS B cells expressed as 
𝚫CT values relative to an 18S endogenous control (paired t test). *, P<0.05.  
I) IPA upstream regulator plot demonstrating enrichment of LPS induced genes in IgMhi TS B 
cells.  
J) IPA upstream regulator plot demonstrating enrichment of retinoic acid induced genes in 
IgMhi TS B cells.  
K) IPA upstream regulator plot demonstrating enrichment of IFN-𝛾 induced genes in IgMlo TS 
B cells.  
L) Bar graphs demonstrating a lower frequency of VH1 and higher frequency of VH3 
immunoglobulin variable heavy chain gene usage in IgMhi TS B cells than TS IgMlo cells (Chi 
squared test with Bonferroni correction). *, P<0.05; ***, P<0.001.  
M) Scatter plot of flow cytometry data from HCD demonstrating that T3 and naïve CD45RBhi 
subsets as gated in Figure 3J share high IgM expression (MFI mean +/- SD, paired t test). 
****, P<0.0001.  
N) T3 and naïve CD45RBhi subsets share similar high surface expression of CD24 (MFI mean 
+/- SD, paired t test). ****, P<0.0001. 
 
Figure S3. Sort strategy, 10x genomics workflow and identification of B cell subsets 
represented by UMAP clusters in 10x HCD 1.  
A) Gating strategy to sort live CD19+ cells.  
B) Total-Seq antibodies and clones used for surface labelling of CD19+ B cells.  
C) Demographic details of HCD, cells captured and sequencing depth.  
D) UMAP plot demonstrating clusters generated from a PCA run on 2000 differentially 
expressed genes from 10x HCD1.  
E) Feature plots demonstrating lineage defining ADT (CITE-Seq antibody) and transcript 
signal overlay on the UMAP plot.  
F) Table of median IgM expression within clusters representing naïve cells (CD27-
IgD+CD38int), the top 30% of clusters were designated as IgMhi.  
G) Merged and pseudocoloured clusters representing B cell subsets defined by ADT and 
gene signal of lineage defining targets.  
H) A 3D UMAP plot demonstrating merged and pseudocoloured clusters representing B cell 
subsets from 10X HCD2.  
I) A 3D UMAP plot demonstrating merged and pseudocoloured clusters representing B cell 
subsets from 10X HCD3. 
 
Figure S4. Patient and HCD demographic tables. 
A) Table of SLE patient demographic data used for Fig. 6 and 7. Eth. = Ethnicity, Neph. = 
lupus nephritis, Cut. = cutaneous lupus, Arth. = Inflammatory arthritis, C = Caucasian, AC = 
African Caribbean, SEA = South East Asian, MMF = mycophenolate mofetil, PRED = 
prednisolone, HCQ = hydroxychloroquine.  
B) Table of HCD demographic data used in Fig. 6. Eth. = Ethnicity, SEA = south east Asian, IA 
= Indian Asian.  
C) Table of demographic data of patients with other autoimmune diseases. GPA = 
granulomatosis with polyangiitis, PV = pemphigus vulgaris, UC = ulcerative colitis, AZA = 
azathioprine, MTX = methotrexate, MES = mesalazine.  
 
Figure S5. The relationship between MZB counts and SLE clinical parameters and a 
proposed model of defective B cell development in SLE.  
A) Scatter plots of flow cytometry data demonstrating no difference in MZB frequency in 
African Caribbean (-AC) and Caucasian (-C) HCD and SLE patients (medians, Mann-Whitney 
test).  
B) Correlation of MZB and SLEDAI score in Caucasian SLE patients (Spearman’s rank 
coefficient).  
C) Bar graphs demonstrating the immunosuppressive burden of SLE patients with low MZB 
counts (< 3.13% CD19+ cells) vs high MZB counts (>3.13% CD19+ cells) where 3.13% 
represents the median MZB value in all SLE patients.  
D) Scatter plots of flow cytometry data demonstrate that pemphigus vulgaris (PV) patients 
taking MMF and / or prednisolone did not have reduced MZB when compared to SLE 
patients on the same immunosuppressive medication (mean +/- SD, unpaired t test).  
E) Scatter plots of flow cytometry data demonstrate there was no difference in MZB counts 
in non-renal SLE (OL) patients taking or not taking hydroxychloroquine (HCQ) therapy 
(medians, Mann-Whitney test).  




Materials and Methods 
 
Lead contact 
Information regarding reagents and resources should be directed to Professor Jo Spencer 
(jo.spencer@kcl.ac.uk).  
 
Data and code availability 
All raw and processed next-generation sequencing data have been deposited with GEO 
under accession numbers GSEXXXXX and GSEXXXXX. Code is available on github 
https://github.com/jspencer-lab/MZBFromT2. 
 
EXPERIMENTAL SUBJECT DETAILS 
All blood and tissue samples were obtained from adults with REC approval and informed 
consent. SLE patients were recruited using the following criteria; i) fulfilment of 4 or more 
revised ACR classification criteria; ii) ANA positive; iii) Biologic (Belimumab or rituximab) 
naïve; iv) Immunosuppressive regimen does not include azathioprine or cyclophosphamide 
within 6 months of sample collection due to the severe depletion of naïve B cells by these 
medications. All LN patients had diagnostic confirmation by renal biopsy. Blood was 
obtained from SLE patients and HCD (REC reference 11/LO/1433: Immune regulation in 
autoimmune rheumatic disease, London – City Road & Hampstead Research Ethics 
Committee). Paired gut biopsies and blood were obtained from individuals undergoing 
colonoscopies in whom no mucosal abnormality was detected (REC reference 11/LO/1274: 
Immunology the intestine; features associated with autoimmunity, London - Camberwell St 
Giles Research Ethics Committee). Samples of cells draining the gut and spleen via the 
hepatic portal vein were obtained from liver perfusion prior to transplantation (REC 
reference 09/H0802/100: The role of innate immune system in hepatic allograft outcome, 








Blood samples were diluted 1:1 in RPMI-1640 containing 10% foetal calf serum (FCS), 100 
U/ml penicillin and 100 μg/ml streptomycin (RPMI-P/S). Diluted blood was then layered 
onto Ficoll and centrifuged for 25 minutes with brake and accelerator set to 0. The buffy 
coat layer was then removed and cells were washed in RPMI-P/S. PBMC isolated from 
patients undergoing colonoscopy was used fresh, whilst PBMC used for the analysis of HCD 
and patients with SLE, UC, GPA and PV was cryopreserved in FCS + 10% dimethyl sulfoxide 
(DMSO).  Mononuclear cells from gut were obtained by the removal of epithelial cells with 
1mM EDTA in HBSS containing 100 U/ml penicillin and 100 μg/ml streptomycin for 30 
minutes. Collagenase digest was then used to generate a cell suspension using collagenase 
D (1 mg/ml) and DNase (10 U/ml) in RPMI-P/S for 1 h. 
 
Mass cytometry 
3 mass cytometry panels were utilized, the staining protocols were as follows.  
Panel 1: Cryopreserved cells were washed and rested in RPMI-P/S + 0.1mg/ml DNase at 37 
degrees for 45 minutes. B cells were then negatively enriched using a Miltenyi B cell 
isolation kit II. 4 x 106 were then viability stained with 1ml cisplatin 25µM in 1x PBS. Cells 
were then washed in PBS containing 0.5% BSA with 2mM EDTA (Cell staining medium, C-SM) 
and resuspended in 10ul Fc receptor blocking solution and left for 10 minutes on ice. IgG 
staining was then performed in 100µl staining volume for 30 minutes on ice. Cells were then 
washed in CS-M and resuspended in the pre-titrated volume of antibody mastermix, the 
volume was then adjusted to 100ul with CS-M and cells were stained for 30 minutes on ice. 
Metal tagged antibodies used are listed in Fig. S1 A. Cells were then washed twice in 1xPBS 
and fixed overnight in 16% paraformaldehyde. The following day cells were washed in 1xPBS 
and DNA was stained with 1µM Intercalatin in 500ul permeabilization buffer at room 
temperature for 20 minutes. Cells were then washed twice in 1xPBS and twice in Milli-Q 
water before being resuspended in Milli-Q water plus EQ beads to a concentration of 0.5 x 
106 /ml and run on a Helios Mass cytometer.  
 
Panel 2: As for panel 1 except cells were stained fresh, were not enriched and 2 x 106 cells 
were viability stained with 1ml rhodium intercalator diluted in 1:500 in PBS for 20 minutes 
at room temperature. Metal tagged antibodies used are listed in Fig. S1A. 
 
Panel 3: As per panel 1 except cells were not enriched and IgG staining was not performed. 
Metal tagged antibodies used are listed in Fig S1A.  
 
Analysis of mass cytometry data 
FCS files were normalised using Nolan lab software (v0.3, available online at 
https://github.com/nolanlab/beadnormalization/releases). A representative pre and post 
normalisation plot is shown in Fig. S1 B. Where files were concatenated the Cytobank FCS 
File Concatenation Tool was used (available online at https://support.cytobank.org/hc/en-
us/articles/206336147-FCS-file-concatenation-tool). Files were then loaded onto the 
Cytobank (https://mrc.cytobank.org/) and gated to identify live CD19+ B cells (Fig. S1 C).  
 
For the analysis of HCD PBMC in Fig. 1, viSNE was run on equal numbers of CD19+ events 
(n=35000) from each HCD (n=10). SPADE was then run on the viSNE coordinates and B cell 
subsets were identified by placing nodes into bubbles. The TS bubble was identified as 
CD27-IgD+CD24+++/++CD38+++/++.  Events within the TS bubble were exported and a further 
viSNE was run using equal events (n=3535) and all panel markers except CD45, CD3, CD14 
and class switched isotypes IgA and IgG which are not expressed by TS B cells. CD45 was 
excluded due to homogenous expression and lack of contribution to clustering. SPADE was 
then run on the viSNE coordinates and TS B cell populations were defined as demonstrated 
in Fig. 1 B. 
 
For the analysis of PBMC and GALT derived B cells in Fig. 2, equal numbers of CD19+ events 
(n=118,934) from concatenated PBMC (n=7) and GALT (n=7) samples were used to run a 
viSNE using all markers except for CD45, CD3 and CD14. SPADE was then run on the viSNE 
coordinates and TS B cells identified as CD27-IgD+CD10+ nodes. Events within the TS bubble 
were then exported and equal numbers of events (n=4520) were clustered using FlowSOM. 
CD10, CD24, CD38, IgM as clustering channels to allow the undirected visualization of 
markers on TS B cell populations.  
For the analysis of PBMC from HCD and SLE samples in Fig. 7, CITRUS was run using equal 
numbers of CD19+ events (n=20000) from HCD (n=8) and SLE patients (n=8) and the 
following clustering channels : CD5, CD9 CD10, CD24, CD27, CD38, CD45RB, IgD, IgM, IgA. 
Due to event sharing amongst CITRUS nodes, node 321672 identified in Fig. 7 A and Ciii 
contains all CD27-IgD+CD24+++/++CD38+++/++ events and was therefore used for analysis of TS 
B cells. All events from this node were exported and FlowSOM was run using equal event 
sampling (n= 657) and using all marker channels except CD45, CD3, CD14 and IgA.  
 
Flow cytometry and cell sorting 
Cryopreserved cells used for flow cytometry were thawed and washed in RPMI-P/S and then 
rested at 37 degrees in RPMI-P/S + 0.1mg/ml DNase for 45 minutes. Viability staining with 
Zombie aqua dye was performed using 100µl 1:200 dilution in 1xPBS, or with DAPI 
0.1mg/ml diluted 1:1000 and added prior to sample acquisition on the flow cytometer. Cells 
were stained on ice for 15 mins with pre-titrated concentrations of antibodies. Staining with 
R123 was performed for 10 minutes at a concentration of 6µM and cells were washed and 
chased for 3 hours in RPMI-P/S. All samples were analysed by a BD LSRFortessa (BD 
Biosciences). Anti-Mouse/Rat beads (BD) were used for fluorescent compensation and gates 
were set using appropriate isotype controls. Cell sorting was performed using a BD FACSAria 
(BD Biosciences) and live single CD19+ B cells were gated as follows IgMhi TS : CD27-
IgD+CD10+IgMhi, IgMlo TS : CD27-IgD+CD10+IgMlo, IgMhi naïve: CD27-IgD+CD10-IgMhi, IgMlo 
naïve : CD27-IgD+CD10-IgMlo, where IgMhi and IgMlo gates captured 30% of the highest and 
lowest IgM expressing cells respectively.  
 
Cytokine detection 
Fresh PBMC was isolated from HCD and incubated for 6 hours at 37 degrees with phorbol 
12-myristate 13-Acetate (PMA) 50ng/ml and Ionomycin 250ng/ml with Golgiplug at a 
dilution of 1:1000. Cells were then surface stained as above followed by fixation with 
Cytofast buffer (Biolegend). Cells were then washed twice and stained with resuspended 
conjugated antibodies in permeabilization / wash buffer (Biolegend) for 20 minutes at room 
temperature.    
 
 
Cell culture and stimulation analysis 
Sorted IgMhi and IgMlo TS and naïve (CD27-IgD+CD10-) B cell subsets were plated onto a 96 
well plate seeded with 2 x 104 cells per well. Wells containing CD40L expressing HEK cells 
were also seeded with 2 x 104 irradiated HEK cells per well. Cells were then stimulated with 
CPG-ODN 2.5µg/ml or anti-IgM 10µg/ml. Proliferation assays were performed on cells 
stained with CellTrace violet as per the manufacturer’s guidelines. Cells were then stained 
and analysed by flow cytometry as above.  
 
Single cell RNA sequencing library preparation  
Sorted cell populations were loaded onto a 10x Genomics Chromium Controller and 5’ gene 
expression, VDJ and ADT (for samples in Fig. 4) were prepared according to the 
manufacturers guidelines. Samples used in Fig. 3 were sequenced using an Illumina NextSeq 
500 platform. Samples used in Fig. 4 were sequenced using an Illumina HiSeq 2500 High 
Output platform. The 10x Genomics Cellranger workflow was then used for transcript 
alignment and the generation of sparse matrices for downstream analysis.  
 
CITE-Seq antibody staining 
Cryopreserved samples were thawed and sorted using the gating strategy in Fig. S3 A. Cells 
were then washed and stained in a CITE-Seq antibody cocktail at a concentration of 8µg/ml 
for 30 minutes on ice (Fig. S3 B). Cells were then washed three times before loading onto 
the 10x Chromium controller.  
 
Single cell sequencing analysis 
The Seurat R package (vs 3.1.1) was used to filter data to remove cells with low numbers of 
RNA transcripts, doublets and cells with high levels of mitochondrial transcripts indicative of 
cell death. Immunoglobulin variable genes were then removed from the dataset as well as 
cells with low expression of B cell genes CD79A, CD79B, CD19 or MS4A1. Data from IgMhi 
and IgMlo TS B cells were merged and the data was transformed in accordance with the 
SCTransform workflow before UMAP based reduction of dimensionality and PCA-based 
clustering to identify populations (Hafmeister, 2020). Heatmaps were then created using 
select genes from the top 60 differentially expressed genes in each sample, and dot plots 
and violin plots on selected genes. Data from sorted CD19+ cells from HCD used for Fig. 4 
and Fig. S3 was initially analysed individually followed by an integrated analysis. Individual 
analysis was performed using the quality control (QC) steps as well as the removal of IGHV 
genes and non- B cells as described above. Data was then normalized and scaled and UMAP 
run on a PCA generated using 2000 variable genes. Overlay of ADT and gene signal, violin 
plots and median expression of markers by UMAP clusters was used to identify which B cell 
subsets they corresponded to. For the integrated data analysis, data from 3 HCD was 
filtered using the QC steps as well as the removal of IGHV genes and non- B cells as 
described above. Data was then normalized using the SCTransform wrapper in Seurat 
followed by integration using The Satija Laboratory Integration and Label Transfer 
protocol (Butler et al., 2018), using 3000 integration features. The 2000 most variable genes 
were then used to perform PCA and a 3-dimensional UMAP was obtained from this. 
Clusters were obtained using the FindNeighbours and FindClusters functions within Seurat, 
using default parameters. The UMAP coordinates and cluster allocations were then used to 
run Slingshot (Street et al., 2018). Randomised downsampling of 50% was required to improve 
the performance of trajectory inference in Slingshot. ADT overlay of the UMAP plot was used 
to identify the cluster composed of CD27-IgD+CD38hi cells that best represented TS B cells 
and this was chosen as the starting point from which Slingshot would build trajectories. A 
heatmap was then created using genes of interest amongst the top 100 differentially 
expressed genes on the trajectory. 
 
Quantitative RT-PCR 
Quantitative RT-PCR was performed using Taqman Gene Expression Assays (FAM, 
Thermofisher Scientific) were used to quantify CCR7 and ITGB7 expression in cDNA from 
sorted IgMhi and IgMlo TS B cell subsets. Reactions were performed in duplicate and 
multiplexed with Eukaryotic 18S rRNA Endogenous Control (VIC).  Samples were run on a 
QuantStudio 5 Real Time PCR System (Thermofisher Scientific). DCT was calculated using 






QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Flow cytometry and mass cytometry data 
Flow cytometry data was visualized and gated using FlowJo v 10.6.1. Mass cytometry data 
was analysed using cytobank software.  
 
Statistical analysis 
Graphpad prism version 7.0 was used for statistical analysis. Paired t tests or Wilcoxon tests 
were used to compare paired samples whilst unpaired t tests or Mann-Whitney tests were 
used for unpaired samples. Adjusted p values were represented as * p=<0.05, ** p=<0.01, 
*** p=<0.001. All error bars show the mean +/- standard deviation.  
 
Online supplemental material 
Fig. S1 illustrates antibody panels, normalization and gating strategy for mass cytometry; 
flow cytometry gating relating to Figs. 2 and 3; and a heatmap relating to Fig. 2B. Fig. S2 
illustrates the sorting strategy, 10x genomics workflow and validation of data in Fig. 3. Fig. 
S3 illustrates the sorting strategy and 10x genomics workflow; identification of B cell subsets 
represented by UMAP clusters in 10x HCD 1 in Fig. 4; and 3D UMAP plots illustrating B cell 
subsets in 10x HCD 2 and 3.  Fig. S4 provides demographic data for patients and healthy 
controls. Fig. S5 illustrates the relationship between MZB counts and SLE clinical parameters 
and also a model of B cell development that includes alterations observed in SLE.  
 
Supplemental videos 
Supplemental video 1. Rotation of the 3D UMAP plot demonstrating B cell subsets from 10x 
HCD1 as depicted in Fig. 4A (see also Fig. S3 D, E, F and G).    
Supplemental video 2. Rotation of the 3D UMAP plot demonstrating B cell subsets from 10x 
HCD2 as demonstrated in Fig. S3 H.   
Supplemental video 3. Rotation of the 3D UMAP plot demonstrating B cell subsets from 10x 
HCD3 as demonstrated in Fig. S3 I.   
Supplemental video 4. Rotation of 3D UMAP plot as depicted in Fig. 4 G with overlay of IgM 
ADT signal demonstrating that the Slingshot trajectory passes through IgMhi naïve B cells.  
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CD38 CD10 β7 integrin CD24 IgM CD21
4.19 1.89 0.44 2.28 4.98 0.40
3.14 0.52 0.03 1.19 3.53 0.11
3.44 0.86 0.83 1.35 3.95 1.13
3.22 0.66 1.51 1.32 4.14 2.60
1.78 0.45 0.80 0.39 2.85 2.07
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